75 results about "Thiazolidine" patented technology

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.

The invention relates to the technical field of organic photoelectric materials, and particularly discloses a non-condensed ring small molecule acceptor material based on a quinonoid structure as well as a preparation method and application of the non-condensed ring small molecule acceptor material. According to the invention, easily available 1, 4-diacetyl piperazine-2, 5-diketone is used as a center, an alkyl chain and Ar are used for modification, EG is used as an end group, the non-condensed ring A-D-A '-D-A type structure acceptor material based on a quinone structure is constructed, and the general formula is shown in the specification. Wherein the PCE of the acceptor material which is modified by bithiophene and takes 2-(3-ethyl-4-oxothiazolidine-2-subunit) malononitrile as a terminal group reaches 15%. The non-condensed ring small molecule acceptor material based on the quinonoid structure is simple in synthesis process, and an effective strategy is provided for solving the problem of the overall performance of an organic solar cell.

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, and processes of using such pesticidal compositions against such pests. The pesticidal compositions comprise (A) an oxathiazolidine derivative of formula one and (B) a mixing partner and may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides.

The invention discloses a chiral amino acid CPL probe based on an aldehyde group functionalized luminescent rare earth spirochete complex as well as a preparation method and application thereof, and belongs to the technical field of biosensing materials. The invention aims to solve the problem that the existing probe has poor selectivity in recognition of sulfydryl amino acid. The chiral amino acid CPL probe is an aldehyde group functionalized water-soluble lanthanide helical complex, side chain aldehyde groups can enhance the water solubility of the helical complex by forming hemiacetal and can also be used as specific recognition sites, the aldehyde groups react with sulfydryl-containing amino acids such as D-penicillamine and L-cysteine to form thiazolidine rings, and the chiral amino acid CPL probe can be used as a specific recognition site. Furthermore, the chirality of D-PA and L-Cys is triggered to be transmitted to a metal center, and the chirality is amplified into a detectable CPL signal. Thiazolidine rings formed by condensation of different amino acids have steric hindrance differences, and the steric hindrance differences can influence spiral chirality, so that the probe still shows excellent selectivity even in a complex system in which a plurality of interfering substances coexist.

The present application relates to the technical field of agricultural chemistry, in particular to butenolide compounds containing a thiazolidinone structure as well as a preparation method therefor and the use thereof. The butenolide compounds containing a thiazolidinone structure are characterized by having the following structural general formula (I). The compounds disclosed by the present application have excellent fungicidal activity on various pathogens in agriculture or other fields, and can favorably protect important crops and domestic animals in agriculture and horticulture industry, and the environment that the human beings rely on from invasion of pathogens.

The invention relates to the technical field of suspending agents, in particular to a suspending agent containing oxine-copper and benziothiazolinone as well as a preparation method and application of the suspending agent. The invention relates to a suspending agent containing oxine-copper and benziothiazolinone, which is prepared from the following raw materials in percentage by mass: 28 to 32 percent of oxine-copper, 4 to 8 percent of benziothiazolinone, 1 to 6 percent of dispersing agent, 1 to 6 percent of wetting dispersant, 1 to 1.5 percent of suspending thixotropic agent, 4 to 8 percent of antifreezing agent, 0.05 to 0.5 percent of preservative, 0.05 to 0.5 percent of thickening agent, 0.1 to 0.5 percent of defoaming agent and the balance of water. The dispersing agent comprises polycarboxylic acid ammonium salt; the invention provides the suspending agent containing oxine-copper and benziothiazolinone, which has the advantages of favorable dispersity, favorable stability and favorable control effect. The suspending agent containing oxine-copper and benziothiazolinone provided by the invention has a good control effect on citrus tree canker and cucumber bacterial angular leaf spot.

The invention relates to a method of producing a food composition comprising microalgal biomass with reduced off-flavour, said method comprising adding at least 0.001 wt.%, calculated by weight of the food product, of an aldehyde scavenger, said aldehyde scavenger containing at least 5 wt.%, calculated by weight of the aldehyde scavenger of cysteine. The invention also relates to Food composition comprising microalgal biomass material, said material comprising at least 5 wt% of microalgal protein by weight of dry matter of the microalgal biomass, and 2-pentyl-1,3-thiazolidine-4-carboxylic acid and / or salts thereof, and optionally, water. The invention also relates to a food composition comprising microalgal biomass material, comprising at least 5 wt% of microalgal protein by weight of dry matter of the microalgal biomass; hexanal or a source of hexanal; and at least 0.001 wt.%, calculated by weight of the food product, of an aldehyde scavenger, said aldehyde scavenger containing at least 5 wt.%, calculated by weight of the aldehyde scavenger of cysteine.

The present disclosure provides thiazolidine (Tz) linkers for protein-drug conjugates. In addition, the disclosure also encompasses compounds useful for producing such protein-drug conjugates, as well as methods for production of such protein-drug conjugates. The disclosure also encompasses methods of using the protein-drug conjugates for the treatment of a disease or disorder in a subject.

The application discloses a kind of chiral PEG-Ag6D / LSP6 cluster-based nanoparticles, method and application, method includes: S1, the preparation of chiral nanocluster, in mixed solvent silver salt and thiazolidine thione ligand is added, and the crystal of chiral silver nanocluster is obtained by volatilization;S2, a certain amount of amphiphilic polymer DSPE-PEG2000 and chiral silver nanocluster are dissolved in organic solvent, then added to a certain volume of aqueous solution;S3, under the condition of violent stirring, reaction is carried out until organic solvent is completely removed, filtration is carried out, and the product is obtained;The chiral PEG-Ag6D / LSP6 cluster-based nanoparticles prepared in the application has good biocompatibility, rapid response to biological thiol, strong anti-interference ability and low detection limit, and is suitable for high-throughput equipment, can be used for biological thiol distinction, enantioselective chiral recognition and biological thiol quantitative detection in plasma, and as potential nanomedicine and exhibit chiral-dependent anti-tumor effect.

The application discloses a FAPI derivative containing 4-cyano thiazolidine modification and application thereof, relates to the field of drug compounds for diagnosing tumors, and provides a FAPI derivative containing 4-cyano thiazolidine modification, a chemical structural formula of which is shown as formula I. The FAPI derivative has good stability, is simple to prepare, has high radiochemical purity and good biological performance, and can be further used for clinical PET / CT tumor imaging, effectively solving the problems of low tumor uptake rate, short retention time and inability to further delay imaging of F-labeled FAPI probes. 18 The FAPI derivative containing 4-cyano thiazolidine modification can solve the problems of low tumor uptake rate, short retention time and inability to further delay imaging of F-labeled FAPI probes, and make up for the defects of the prior art.

The present invention belongs to the field of medicinal chemistry and relates to a triazine-thiazolidinone compound and its preparation method and application. Its structural formula is wherein R1 is any one of alkyl, pyranyl, indolyl, phenyl or thienyl. Its pharmaceutically acceptable salt is the acid salt of the compound, and the acid is any one of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, boric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, benzenesulfonic acid, citric acid, lactic acid, pyruvic acid, tartaric acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, salicylic acid or phenylacetic acid. The triazine-thiazolidinone compound skeleton provided by the present invention is novel, has a good inhibitory effect on glucose transporter 1 (GLUT1), and its inhibitory effect in HT29 cells is much better than that of positive control compound BAY-876, with good potential for further development as an anti-tumor drug.

Compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5, and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

The invention discloses application of a quinoline compound to prevention and treatment of ralstonia solanacearum, and belongs to the technical field of prevention and treatment of plant bacterial wilt. The quinoline compound is 1-ethyl-6-fluoro-7-morpholinyl-3-(3-(p-tolyl)-1, 2, 4-oxadiazole-5-yl) quinoline-4 (1H)-ketone, and it is found for the first time that the 1-ethyl-6-fluoro-7-morpholinyl-3-(3-(p-tolyl)-1, 2, 4-oxadiazole-5-yl) quinoline-4 (1H)-ketone has very strong inhibitory activity on Ralstonia solanacearum, and the quinoline compound can be used for preparing a compound for inhibiting Ralstonia solanacearum. Experiments show that the MIC of the 1-ethyl-6-fluoro-7-morpholinyl-3-(3-(p-tolyl)-1, 2, 4-oxadiazole-5-yl) quinoline-4 (1H)-ketone to ralstonia solanacearum is 5 [mu] g / mL within 24 h, which is equivalent to that of benziothiazolinone, so that the 1-ethyl-6-fluoro-7-morpholinyl-3-(3-(p-tolyl)-1, 2, 4-oxadiazole-5-yl) quinoline-4 (1H)-ketone can be used for preventing and treating plant bacterial wilt, and a new candidate compound is provided for development of ralstonia solanacearum bactericides.

The invention relates to a novel N-(2-(4-cyano thiazolidine-3-yl)-2-oxyethyl) quinoline-4-formamide derivative and a preparation method of the N-(2-(4-cyano thiazolidine-3-yl)-2-oxyethyl) quinoline-4-formamide derivative. The structure of the compound or the pharmaceutically acceptable salt is C-A-B, A is a quinoline ring, B is an (R)-3-glycyl thiazolidine-4-nitrile side chain, and C is a side chain containing a sulfoximine structure. The compound or the pharmaceutically acceptable salt of the compound, and the pharmaceutical composition containing the compound or the pharmaceutically acceptable salt of the compound have obvious FAP enzyme inhibition activity, and can be used for preparing an FAP small-molecule inhibitor.

The present invention discloses a pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain, and its preparation method and application. The preparation method is as follows: first, pleuromutilin and p-toluenesulfonyl chloride are added to methyl tert-butyl ether, sodium hydroxide solution is added dropwise with stirring, and the reaction is refluxed to obtain intermediate 1; then, 2-thio-4-thiazolidinone is added to acetonitrile, anhydrous potassium carbonate is added and stirred at room temperature for 20 minutes, and then intermediate 1 is added, and the reaction is stirred at room temperature for a certain time to obtain intermediate 2; finally, intermediate 2 and an acyl chloride with different group donors are added to dichloromethane, and under the catalysis of triethylamine, stirred at room temperature for a certain time to obtain a pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain. The present invention synthesizes a pleuromutilin derivative containing a 2-thio-4-thiazolidinone side chain with good antibacterial activity through a simple preparation process, with high yield, good antibacterial activity against drug-resistant bacteria, and good application prospects.

This invention discloses a novel thiazolidinone-based amphoteric Gemini surfactant, its preparation method, and its application. The surfactant's molecule contains two thiazolidinone groups and a long hydrophobic chain, represented by the following formula 1. This surfactant, when combined with an inorganic salt, can produce a clean fracturing fluid exhibiting excellent viscoelasticity, shear resistance, and rheological properties in low-temperature environments. This fracturing fluid complies with national petroleum and natural gas industry standards and exhibits excellent sand-carrying performance, no residue, and high temperature resistance. Furthermore, it is easy to prepare on-site and can effectively remove gel-breaking substances. This fluid causes minimal damage to formations and requires a low fracturing margin, making it suitable for natural gas hydrate extraction in low-temperature, high-pressure deep-sea areas. #imgabs0#

The present invention relates to novel cyclic compounds; a method for the solid phase synthesis of said novel cyclic compounds; novel thiazolidine and oxazolidine building blocks that can be directly incorporated into the solid phase synthesis of said novel cyclic compounds, and a novel method for the synthesis of said thiazolidine and oxazolidine building blocks; and cosmetic compositions containing said novel cyclic compounds.

The application discloses an epoxy thermosetting resin containing a thiazolidine dynamic co-curing component and a preparation and recovery method thereof, and belongs to the technical field of polymer materials and thermosetting resins. The thiazolidine dynamic co-curing component is a compound containing a thiazolidine structure, at least one thiazolidine ring and at least two carboxyl groups capable of participating in an epoxy curing reaction. The application introduces the dynamic co-curing unit containing the thiazolidine structure by partially replacing the curing component, realizes low-disturbance dynamic modification without completely reconstructing a traditional epoxy system, has little influence on the compatibility of an original formula and the comprehensive performance of a material. The double-response characteristics of the thiazolidine structure embedded in the network can trigger network topology rearrangement at high temperature, endow the material with stress relaxation, self-repairing, hot welding and hot pressing reprocessing capacity, and can also cause selective cleavage under acidic conditions, realize chemical deconstruction of the crosslinking network, and have good application prospect.

The present invention relates to the technical field of materials, and particularly discloses a high refractive index polyimide optical material and a preparation method thereof, the high refractive index polyimide optical material comprises: a diamine component, the diamine component comprises 30-70 mol% of a sulfur-containing heterocyclic diamine selected from at least one of 4, 5-thiazolidine-2-thiol diamine, 1, 3, 4-thiazolidinedithiol diamine and 2-methylthiopyrimidine-4, 6-diamine, and the diamine component comprises at least one of 4, 5-thiazolidine-2-thiol diamine, 1, 3, 4-thiazolidinedithiol diamine, 1, 3, 4-thiazolidinedithiol diamine and 2-methylthiopyrimidine-4, 6-diamine; 5-40 mol% of a diamine monomer containing a tertiary amino group; 0 to 65 mol% of an aromatic or aliphatic diamine; the dianhydride component comprises at least one sulfur-containing dianhydride monomer, and the sulfur-containing dianhydride monomer contains a sulfur sulfuryl (-SO2-) or thioether bond (-S-) structural unit; according to the present invention, the synergistic combination of sulfur-containing heterocyclic diamine and tertiary amino-containing diamine is introduced, and the structural design of sulfur-containing dianhydride is matched, such that the electron cloud density and the molecular polarization are improved at the molecular level;

The invention discloses a modified polyester film for an automobile window and a preparation method of the modified polyester film, and relates to the technical field of polyester films. When the modified polyester film for the automobile window is prepared, firstly, methyl p-hydroxycinnamate reacts with [chlorine (ethyoxyl) phosphonyl] benzene to prepare a modified phosphorus-containing cinnamic acid diester compound; the preparation method comprises the following steps: reacting nano antimony tin oxide with a silane coupling agent to prepare pre-modified nano antimony tin oxide; the pre-modified nano tin antimony oxide is subjected to a reaction with thiazolidine acid, 6-maleimido-1-hexanal and ethyl isocyano acetate, and modified nano tin antimony oxide is prepared; carrying out copolycondensation on terephthalic acid, ethylene glycol, the modified phosphorus-containing cinnamic acid diester compound, 2, 2 '-difuran-5, 5'-dicarboxylic acid dimethyl ester and the modified nano tin antimony oxide to obtain modified polyester; and carrying out hot-pressing film formation on the modified polyester to obtain the modified polyester film for the automobile window. The prepared modified polyester film for the automobile window has the advantages of flame retardance, ultraviolet shielding, heat insulation, self-repairing and aging resistance.

Compounds having the structure of formula (I) and their pharmaceutically acceptable salts are disclosed, wherein X 1 R 1 R 2 R 3 R 4 R 5 and R 6 This refers to: pharmaceutical compositions comprising such compounds and salts as defined in the specification; the use of such compounds and salts for the treatment or prevention of prolyl endopeptidase fibroblast activation protein (FAP)-mediated diseases; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts. Formula (I):

The pharmaceutical compound or the pharmaceutically acceptable salt thereof is used for preventing or treating the following diseases by simultaneously inhibiting autotaxin (ATX) and activating peroxisome proliferator-activated receptor gamma (PPAR gamma): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases, and b) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases; the present invention relates to a pharmaceutical composition for treating hepatitis, such as various hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where said ILD may be a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or said ILD is a complication associated with an autoimmune and / or inflammatory and / or metabolic disease, or a pharmaceutical composition comprising said ILD. Preferably rheumatoid arthritis ILD and / or scleroderma ILD and / or myositis ILD and / or diabetes ILD and / or cardiovascular disease ILD; and / or b) inflammatory and / or autoimmune diseases, preferably rheumatoid arthritis and / or scleroderma; and / or c) cancer, in particular lung and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma; and / or d) a metabolic disease, in particular diabetes mellitus type 1 and / or diabetes mellitus type 2 and / or obesity, having a formula selected from the group consisting of formulae (A), (B), (C), (D), (E), (F), (G) and (H).

Solid-state forms of N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide; corresponding pharmaceutical compositions; uses to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits; and methods of preparation.

Disclosed herein are crystalline forms of (Z)-1-(2-fluoro-4-(1-(4-(trifluoromethoxy)phenyl-1H-1,2,4-triazol-3-yl)phenyl)-3-(3-(5-methyl-2-((2,2,2-trifluoroethoxy)methyl)phenyl)-4-oxothiazolidin-2-ylidene)urea (Z1), processes for making them and use in agrochemical preparations.

In some aspects, this disclosure relates to methods for preparing cysteine ​​source solutions containing thiazolidinediones. In some other aspects, this disclosure relates to methods for using these cysteine ​​source solutions (such as in the preparation of cell culture media, cell culture, and / or peptide production), and systems and kits comprising these cysteine ​​source solutions.

The invention discloses a thiazolidinone compound and a preparation method and application thereof.The structural formula of the thiazolidinone compound is shown in the formula (II), and the preparation method of the thiazolidinone compound comprises the steps that 4-bromobenzene isothiocyanate and pyridine-4-formyl hydrazine serve as raw materials to react to obtain a product (I); and preparing the thiazolidinone compound (II) by taking the product (I) and chloroacetic acid as raw materials. The thiazolidinone compound disclosed by the invention shows antibacterial activity, particularly has good antibacterial activity on haemophilus influenzae, and can be used as an antibacterial agent.

The present invention relates to pharmaceutical compositions comprising 5-(4-(2-((6-(4-methoxyphenoxy)pyrimidin-4-yl)(methyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione, and salts and co-crystal forms thereof, for the treatment of diseases, processes for the preparation of such formulations, and pharmacokinetic parameters controlled by the formulations.

Disclosed herein are compositions comprising A) compound of Formula One (F1) or Formula Two (F2); and B) biological agent selected from the group consisting of Bacillus species, Baclovirus species, Pseudomonas species, Beauveria species, Mycobacterium species, Mycorrhizal fungi, Trichoderma species, and Metarhizium species.

This invention discloses a benzylpiperidine-containing thiazoline-2,4-dione derivative, its preparation method, and its application, belonging to the field of pesticide synthesis and application technology. This invention synthesizes a series of benzylpiperidine-containing thiazoline-2,4-dione derivatives by combining the highly active benzylpiperidine group with a thiazoline-2,4-dione structure via flexible bonds. Through tests on the inhibitory activity of the synthesized benzylpiperidine-containing thiazoline-2,4-dione derivatives against plant pathogenic fungi, it was found that the benzylpiperidine-containing thiazoline-2,4-dione derivatives synthesized in this invention can effectively inhibit plant pathogenic fungi, especially rice sheath blight pathogen.